Skip to main content
main-content
Top

07-30-2018 | Blood glucose monitoring | Article

Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement

Journal:
Acta Diabetologica

Authors: Maria Chiara Rossi, Giuseppe Lucisano, Antonio Ceriello, Chiara Mazzucchelli, Nicoletta Musacchio, Alessandro Ozzello, Antonio Nicolucci, Paolo Di Bartolo, the AMD Annals-SMBG Study Group

Publisher: Springer Milan

Abstract

Aims

To assess use of self-monitoring of blood glucose (SMBG) in type 2 diabetes (T2DM) in the context of a continuous quality improvement initiative (AMD Annals).

Methods

14 quality-of-care indicators were developed, including frequency of SMBG, fasting blood glucose (FBG), and post-prandial glucose (PPG) levels, and hypoglycemia and hyperglycemia episodes. Clinical data and SMBG values downloaded from any glucose meter were obtained from electronic medical records. The most frequently used glucose-lowering treatment regimens were identified and the indicators were assessed separately by regimen.

Results

Overall, 21 Italian centers and 13,331 patients (accounting for 35,657 HbA1c tests and 8.44 million SMBG values collected during 2014 and 2015) were included in the analysis; 11 therapeutic regimens were selected. Patients in regimens not including insulin performed 15–23 measurements per patient-month, those treated with basal insulin 32.1 tests/patient-month, and those treated with basal and short-acting insulin 53–58 tests/patient-month. In all treatment regimens, PPG measurements represented a minority of all tests; pre-breakfast measurements accounted for about 50% of all FBG values. Mean FBG levels exceeded 130 mg/dl in 49.3–88.3% of the cases in the different treatment regimens, while PPG levels were over 140 mg/dl in 46.7–81.0%. From 5.7 to 32.7%, patients in the different regimens had at least one episode of hypoglycemia (< 70 mg/dl), while from 3.7 to 47.7% had at least one episode of hyperglycemia (> 300 mg/dl).

Conclusions

SMBG is underutilized in patients with T2DM treated or not with insulin. In all treatment groups, PPG is seldom investigated. Poor metabolic control and rates of hyper- and hypoglycemia deserve consideration in all treatment groups.

Please log in to get access to this content

Related topics